Kelyniam Global Inc. Announces Record Revenues
15 Janeiro 2013 - 11:15AM
Third Quarter
Kelyniam is pleased to announce record quarterly revenues of
$382,177 for the third quarter ending September 30th 2012.
This represents almost double the product revenue produced in the
second quarter 2012. The company continues to penetrate the
custom cranial implant marketplace and has sold implants to medical
institutions in more than 20 different states. Furthermore,
the company has sold the first maxiofacial implants in the fourth
quarter as a result of the recent FDA 510k approval in late third
quarter.
Fourth Quarter
The debut of Kelyniam maxiofacial implants in the fourth quarter
was met with orders. These orders combined with existing
custom cranial implant orders propelled revenues to approximately
$400,000 for the fourth quarter, exceeding internal expectations of
a slow quarter due to multiple holidays and fewer surgeries.
Final fourth quarter numbers will be released once a full
accounting is complete.
"The final two quarters of the year demonstrate that both the
custom cranial and maxiofacial implant markets have capacity for a
product of superior design. Management has worked hard to
right the ship in 2012 and looks to build on the momentum in 2013"
stated President and CEO Tennyson Anthony. "Kelyniam not only
has created a product that fills the patient's cranial void, but is
filling the void in the marketplace for a timely-delivered
well-fitting product."
Upcoming Conference
Kelyniam will be exhibiting once again at the North American
Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.
Financial tables can be found on the company's website
www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use
of CAD/CAM technology to provide patient specific custom implants
to assist medical professionals by allowing them to operate more
effectively, improve patient care, and reduce health care costs by
providing the highest quality products available with today's
technology. The company is continually researching and developing
new products and processes to help patients live more active and
productive lives.
Please visit our website at www.kelyniam.com for more
information.
Forward-Looking Statements
Except for historical information contained in this release, the
matters discussed are forward-looking statements that involve risks
and uncertainties. When used in this release, words such as
"anticipate," "believes," "estimate," "expect," "should," "intend,"
"projects," "objective" and "appears" and similar expressions, as
they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are
based on the beliefs of the Company's management, as well as
assumptions made by and information currently available to the
Company's management. Among the factors that could cause actual
results to differ materially are the following: the effect of
business and economic conditions; the impact of competitive
products and pricing; capacity and supply constraints or
difficulties; product development, commercialization or
technological difficulties; the regulatory and trade environment;
the impact of reimbursement rates and coverage; and the risk
factors reported from time to time in the Company's SEC reports.
The Company undertakes no obligation to revise any forward-looking
statements as a result of future events or developments.
Kelyniam Global (PK) (USOTC:KLYG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Kelyniam Global (PK) (USOTC:KLYG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024